Extending its duration of action has become a key focus in drug development
However, higher doses also produced higher rates of gastrointestinal side effects
This paper extends our current knowledge of the effectiveness of this class of medications. Weighing benefits and risks The greatest risk increases were seen for nausea and vomiting, kidney stones, gastroesophageal reflux disease or GERD, sleep disturbances and non-infectious gastroenteritis, which is inflammation of the digestive tract which can cause nausea, vomiting, diarrhea and stomach cramps
Stay tuned for more updates from upcoming clinical trials and FDA regulatory milestones
Other FDA-approved drugs, including donepezil, galantamine, rivastigmine, and memantine, have demonstrated cognitive benefits but are frequently associated with gastrointestinal disturbances, dizziness, agitation, and, in some cases, severe hepatotoxicity, as observed with tacrine (Marucci et al., 2021
In tolerable doses, they rarely achieve 10% weight loss